Loading chat...
HI HB2170
Bill
Status
Introduced
1/26/2022
Primary Sponsor
Scott Saiki
Click for details
AI Summary
- Requires medical directors of methadone treatment programs to conduct medical evaluations including testing for hepatitis C virus infection before admitting applicants to treatment
- Allows use of either laboratory tests or Clinical Laboratory Improvement Amendments-waived rapid point-of-care tests for hepatitis C screening, with laboratory confirmatory testing required for waived test results
- Mandates that methadone treatment programs establish policies and procedures for screening and referrals for care and curative treatment through on-site or external partners
- Permits exceptions to hepatitis C testing when the medical director determines an applicant's subcutaneous veins are severely damaged and a blood specimen cannot be obtained
- Updates statutory language by changing "which" to "that" in the definition of "state authority" and adds definition of "waived test"
Legislative Description
Relating To Methadone Treatment Programs.
Last Action
Referred to HHH, CPC, referral sheet 3
1/28/2022
Committee Referrals
Health, Human Services, & Homelessness1/28/2022
Full Bill Text
No bill text available